(629 Kb) Now

The approval and reimbursement of selpercatinib for RET-positive advanced NSCLC was supported by comparing trial data against RWE from databases like Flatiron Health . 3. Evaluating Quality of Care

As lung cancer is increasingly redefined by specific genetic mutations (e.g., ROS1, RET, NTRK fusions), patient subgroups become extremely small—sometimes representing only 1% of cases.

While the lung cancer article is a primary match for those specific keywords, "629 KB" also appears in these technical and medical contexts: (629 KB)

Patients with comorbidities like COPD or cardiovascular disease are often ineligible for trials, leaving a gap in data regarding how they will respond to new therapies like immune-checkpoint inhibitors. 2. Rare Molecular Subsets

Atypical rearrangement involving 3′-IGH@ and a breakpoint ... - PMC While the lung cancer article is a primary

Traditional clinical trials often exclude "real-world" patients, such as:

In cases where randomized trials are impossible due to small patient populations, RWE has been used to supplement single-arm trials for drug approvals. - PMC Traditional clinical trials often exclude "real-world"

Research identifying a "gene desert" region upstream of the MYC gene (extending up to 629 Kb) which contains risk factors for cancers like Chronic Lymphocytic Leukemia (CLL).